Results 71 to 80 of about 22,017 (188)

Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways

open access: yesIndian Journal of Ophthalmology, 2019
A 30-year-old insomniac, an off-label user of quetiapine, presented with blurring of central vision, eventually diagnosed as central serous chorioretinopathy.
Manish Jain
doaj   +1 more source

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Medication burden in older patients with chronic kidney disease (CKD) is substantial, and simple medication counts are insufficient for identifying those at elevated risk of inappropriate prescribing. This study characterized medication burden by assessing the number of medications, potentially inappropriate medications (PIMs) and ...
Morten Baltzer Houlind   +4 more
wiley   +1 more source

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older‐Age Bipolar Disorder ISBD Task Forces

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Background Cognitive impairment is common in bipolar disorder (BD), but the underlying pathophysiology remains unclear. This systematic review aimed to (1) summarize all literature describing relationships of biofluid biomarkers and cognition in BD and (2) identify which biofluid biomarkers correlate most consistently with cognition in BD ...
Alexandra J. M. Beunders   +21 more
wiley   +1 more source

Lithium Dispensing Patterns in Dutch Youth: Prevalence, Incidence Dosages, and Duration of Use From 2011 to 2022

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Objective Bipolar disorder (BD) often emerges during mid‐adolescence and young adulthood, and leads to functional and social impairment, with a prevalence of 0.87% among Dutch youth. Lithium, the first‐line BD maintenance treatment, stabilizes mood, prevents suicide, and is well tolerated, yet its use has declined as long‐term second ...
Ravish N. Gangapersad   +8 more
wiley   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang   +3 more
wiley   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

open access: yesAdvanced Science, Volume 13, Issue 37, 3 July 2026.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak   +9 more
wiley   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2203-2211, July 2026.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres   +8 more
wiley   +1 more source

Reversible global aphasia as a side effect of quetiapine: a case report and literature review

open access: yesNeuropsychiatric Disease and Treatment, 2017
Ching-Fang Chien,1 Poyin Huang,1,2 Sun-Wung Hsieh1,2 1Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 2Department of Neurology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan Abstract: Quetiapine is an ...
Chien CF, Huang P, Hsieh SW
doaj  

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 1957-1976, July 2026.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway   +24 more
wiley   +1 more source

Convulsive syncope related to a small dose of quetiapine in an adolescent with bipolar disorder

open access: yesNeuropsychiatric Disease and Treatment, 2017
Jianbo Lai,1,2 Qiaoqiao Lu,3 Tingting Huang,3 Shaohua Hu,1,2 Yi Xu1,2 1Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine, 2Key Laboratory of Mental Disorder Management in Zhejiang Province, 3Department of ...
Lai J, Lu Q, Huang T, Hu S, Xu Y
doaj  

Home - About - Disclaimer - Privacy